- Cantor Fitzgerald has initiated coverage on Theratechnologies Inc (NASDAQ:THTX) with an Overweight rating and a price target of $9.
- Theratechnologies’ two HIV drugs, Egrifta and Trogarzo, could grow 20% a year for the foreseeable future, the analyst writes.
- Being conservative, Cantor has modeled a mid-teens sales growth for these two products.
- Product innovations and dedicated sales focus on these two drugs have driven uptake.
- THTX’s decision to internalize its field force and strengthen its commercial operations in the U.S. is starting to deliver results, as evidenced by the 19% Y/Y sales growth in this territory in 3Q22.
- For FY22, the company says it is on track to be around $79 million – $82 million, or growth of the commercial portfolio of 13%-17% Y/Y.
- Cantor writes that the company’s HIV franchise is a source of funds to help build its oncology and NASH pipelines.
- In July, Theratechnologies issued an update on the dose escalation portion of the TH1902 Phase 1 safety study.
- The data came from 18 heavily pretreated patients with sortilin- (SORT1) expressing cancers.
- No Dose Limiting Toxicities were observed during the first cycle.
- Price Action: THTX shares are up 18.60% at $2.23 on the last check Thursday.
Microsoft Analyst Sees Solid Lead Generation From Latest Event
Wells Fargo analyst Michael Turrin reiterated an Overweight on Microsoft Corp (NASDAQ:MSFT) and a $315 price target. Turrin attended Microsoft Ignite in…
